Startups & Innovations – COVID Innovations

The University of California, Irvine said it has developed a low-cost, rapid coronavirus antibody detection platform that can read diagnostics tests. It could be ready for commercialization by the end of the year. UCI is working with Irvine startups Nanommune Inc., which is led by Phil Felgner, director of the Vaccine R&D Center at UCI, and Velox Biosystems Inc. to scale the platform for use in U.S. and abroad. [Subscription required, you can request an electronic copy of the article by sending an email to]